Amgen Agrees To End Neulasta IP Suit Against Pfizer, Hospira
Biopharmaceutical company Amgen has agreed to drop its patent infringement suit against its rivals, Pfizer and Hospira, asking a Delaware federal judge Monday to end the two-year feud over claims of...To view the full article, register now.
Already a subscriber? Click here to view full article